SEC Form 4 · accession 0001209191-17-052901
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Graney
Officer — Chief Financial Officer
Period of report
Sep 13, 2017
Accepted (ET)
Sep 15, 2017 · 8:28 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 13, 2017 | A | 9,566 | $0.00 | A | 9,566 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Restricted stock unit award that vests as to 25% of the shares on December 31, 2017 and an additional 25% of the shares on each of September 30, 2018, 2019 and 2020.